OBJECTIVE: The primary objective of this study was to delineate differences in management, overall and distant disease-free survival in males diagnosed with breast cancer and treated at The Ohio State University Comprehensive Cancer Center as compared to comprehensively matched female subjects. Secondary objectives included assessment of clinical and histopathologic features and recurrence score, as measured by Oncotype DX and the modified Magee equation #2. MATERIALS AND METHODS: This single institution retrospective study compared male and comprehensively matched female patients (1:2) with stage I-III breast cancer between 1994 and 2014. Recurrence risk was estimated using a modified Magee equation. Overall survival and distant disease-free survival were estimated and compared using Kaplan-Meier and Log-rank methods. RESULTS: Forty-five male breast cancer patients were included (stage I: 26.7%; stage II: 53.3%; stage III: 20.0%; hormone receptor positive: 97.8%; human epidermal growth factor receptor 2 negative: 84.4%) with a median age of 63.8 (43.0-79.4) years at diagnosis. Intermediate and low recurrence scores were most common in male and female patients respectively; mean score was similar between groups (20.3 vs. 19.8). The proportion of male breast cancer patients treated with adjuvant chemotherapy and post-mastectomy radiation was lower compared to female patients (42.2% vs. 65.3%, p=0.013; 22.7% vs. 44.4%, p=0.030, respectively). Overall survival and distant disease-free survival between male and female patients were similar. CONCLUSION: Male breast cancer patient outcomes were similar compared to well-matched female patients suggesting that breast cancer specific factors are more prognostic than gender.
OBJECTIVE: The primary objective of this study was to delineate differences in management, overall and distant disease-free survival in males diagnosed with breast cancer and treated at The Ohio State University Comprehensive Cancer Center as compared to comprehensively matched female subjects. Secondary objectives included assessment of clinical and histopathologic features and recurrence score, as measured by Oncotype DX and the modified Magee equation #2. MATERIALS AND METHODS: This single institution retrospective study compared male and comprehensively matched female patients (1:2) with stage I-III breast cancer between 1994 and 2014. Recurrence risk was estimated using a modified Magee equation. Overall survival and distant disease-free survival were estimated and compared using Kaplan-Meier and Log-rank methods. RESULTS: Forty-five male breast cancer patients were included (stage I: 26.7%; stage II: 53.3%; stage III: 20.0%; hormone receptor positive: 97.8%; human epidermal growth factor receptor 2 negative: 84.4%) with a median age of 63.8 (43.0-79.4) years at diagnosis. Intermediate and low recurrence scores were most common in male and female patients respectively; mean score was similar between groups (20.3 vs. 19.8). The proportion of male breast cancer patients treated with adjuvant chemotherapy and post-mastectomy radiation was lower compared to female patients (42.2% vs. 65.3%, p=0.013; 22.7% vs. 44.4%, p=0.030, respectively). Overall survival and distant disease-free survival between male and female patients were similar. CONCLUSION: Male breast cancer patient outcomes were similar compared to well-matched female patients suggesting that breast cancer specific factors are more prognostic than gender.
Authors: José Pablo Leone; Julieta Leone; Ariel Osvaldo Zwenger; Julián Iturbe; Carlos Teodoro Vallejo; Bernardo Amadeo Leone Journal: Breast Cancer Res Treat Date: 2015-07-01 Impact factor: 4.872
Authors: B Cutuli; C Cohen-Solal Le-Nir; D Serin; Y Kirova; Z Gaci; C Lemanski; B De Lafontan; M Zoubir; P Maingon; H Mignotte; C Tunon de Lara; J Edeline; F Penault-Llorca; P Romestaing; C Delva; B Comet; Y Belkacemi Journal: Crit Rev Oncol Hematol Date: 2009-05-12 Impact factor: 6.312
Authors: Suleiman Alfred Massarweh; George W Sledge; Dave P Miller; Debbie McCullough; Valentina I Petkov; Steven Shak Journal: J Clin Oncol Date: 2018-03-27 Impact factor: 44.544
Authors: B Cutuli; M Lacroze; J M Dilhuydy; M Velten; B De Lafontan; C Marchal; M Resbeut; Y Graic; F Campana; V Moncho-Bernier Journal: Eur J Cancer Date: 1995-11 Impact factor: 9.162
Authors: P I Borgen; G Y Wong; V Vlamis; C Potter; B Hoffmann; D W Kinne; M P Osborne; W M McKinnon Journal: Ann Surg Date: 1992-05 Impact factor: 12.969
Authors: Matthew G Davey; Ciara M Davey; Luis Bouz; Eoin Kerin; Carson McFeetors; Aoife J Lowery; Michael J Kerin Journal: Breast Date: 2022-04-28 Impact factor: 4.254